Evidence map›Paper›PMID 33410990›Full record

ArticlePsychopharmacology2021

Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210.

Antonia Serrano, Evelyn Vadas, Belen Ferrer, Ainhoa Bilbao, Noelia Granado, Juan Suárez, Francisco Javier Pavon, Rosario Moratalla, Fernando Rodríguez de Fonseca

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Antonia SerranoInstituto IBIMA, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, 29010, Malaga, Spain. antonia.serrano@ibima.eu.
Evelyn VadasInstituto IBIMA, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, 29010, Malaga, Spain.
Belen FerrerInstituto IBIMA, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, 29010, Malaga, Spain.
Ainhoa BilbaoInstitute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty of Mannheim, University of Heidelberg, Heidelberg, Germany.
Noelia GranadoInstituto Cajal, Consejo Superior de Investigaciones Cientificas (CSIC), 28002, Madrid, Spain.
Juan SuárezInstituto IBIMA, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, 29010, Malaga, Spain.
Francisco Javier PavonInstituto IBIMA, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, 29010, Malaga, Spain.
Rosario MoratallaInstituto Cajal, Consejo Superior de Investigaciones Cientificas (CSIC), 28002, Madrid, Spain.
Fernando Rodríguez de FonsecaInstituto IBIMA, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, 29010, Malaga, Spain. fernando.rodriguez@ibima.eu.ORCID http://orcid.org/0000-0002-4516-5795
Hospital Regional Universitario de Málaga · ESConsejo Superior de Investigaciones Científicas · ESHeidelberg University · DE

Funding

Instituto de Salud Carlos III PI19/1577
6 · The paper itself

Abstract

rationaleThe emergence of the consumption of highly potent synthetic cannabinoid receptor agonists (spice drugs) that produce important neurological symptoms has prompted the research on the consequences of acute and chronic use of these new psychoactive substances. Most studies on cannabinoid dependence have been performed in male animals, and there is a need of studies using female subjects.

objectivesIn the present study, we evaluated only in female animals the role of dopamine D1 receptors in the behavioral responses induced by acute and repeated stimulation of cannabinoid CB1 receptors, including the development of physical dependence, since cannabinoid CB1 receptors are co-localized with dopamine D1 receptors on GABAergic neurons projecting to the substantia nigra.

methodsTo this end, female dopamine D1 receptor-deficient mice and wild-type littermates were treated with HU-210, a potent synthetic cannabinoid agonist.

resultsMutant mice displayed an enhanced response to acute motor and hypothermic effects to HU-210 when compared with wild-type females. The administration of SR141716A precipitated behavioral signs of withdrawal in mice treated subchronically with HU-210. Severity of cannabinoid withdrawal syndrome was potentiated in dopamine D1-deficient female mice. Indeed, 4 of 6 abstinence signs were increased in mutant mice.

conclusionsThese results support for a role of dopamine D1 receptors in the acute, chronic, and withdrawal actions of spice drugs.

Indexed as

AnimalsBehavior, AnimalCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsDose-Response Relationship, DrugDronabinolFemaleMaleMiceMice, KnockoutMotor ActivityReceptor, Cannabinoid, CB1Receptors, Dopamine D1Receptors, Dopamine D2RimonabantSubstance Withdrawal SyndromeCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsDronabinolHU 211Receptor, Cannabinoid, CB1Receptors, Dopamine D1Receptors, Dopamine D2RimonabantD1-deficient miceDopamine receptorsHU-210SR141716AWithdrawal

Identifiers

PMID33410990
OpenAlexW3118932991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.